Literature DB >> 21426448

Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis.

Nobuaki Azemoto1, Teru Kumagi, Masanori Abe, Ichiro Konishi, Bunzo Matsuura, Yoichi Hiasa, Morikazu Onji.   

Abstract

AIM: There is an ongoing need for predictors of long-term outcomes for patients with primary biliary cirrhosis (PBC). Biochemical response to ursodeoxycholic acid (UDCA) has been introduced to predict development of symptoms by our group (Ehime criteria) and to predict long-term outcomes in Western countries (Paris, Barcelona and Rotterdam criteria). The aim of this study was to evaluate whether these criteria are also useful to predict long-term outcomes in Japanese patients with PBC.
METHODS: A retrospective chart review was conducted for 227 Japanese patients with PBC. Patients taking UDCA with an observation period of more than 6 months were included in the study. Data collection included demographics, biochemical and serological markers, and histological stage. Four different criteria regarding biochemical response to UDCA were compared and evaluated.
RESULTS: In total, 138 patients met the inclusion criteria and underwent analysis. Using the Ehime criteria, the transplant-free survival rate was significantly higher in responders than in non-responders (P = 0.010). The Paris criteria also predicted long-term outcomes in our population (P = 0.003), whereas the Barcelona and Rotterdam criteria showed no such association (P = 0.282 and P = 0.553, respectively).
CONCLUSION: Good biochemical response to UDCA according to the Ehime and Paris criteria is associated with long-term outcome in Japanese patients with PBC and allows identification of non-responders who may benefit from further trials. Finally, Ehime criteria should be validated in a different patient cohort.
© 2011 The Japan Society of Hepatology.

Entities:  

Year:  2011        PMID: 21426448     DOI: 10.1111/j.1872-034X.2011.00782.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

1.  Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis.

Authors:  Xiaoli Fan; Ruoting Men; Ping Ni; Changli Lu; Tengfei Si; Yun Ma; Li Yang
Journal:  Clin Rheumatol       Date:  2019-12-06       Impact factor: 2.980

Review 2.  Advances in pharmacotherapy for primary biliary cirrhosis.

Authors:  Hani S Mousa; Ana Lleo; Pietro Invernizzi; Christopher L Bowlus; Merril Eric Gershwin
Journal:  Expert Opin Pharmacother       Date:  2014-12-29       Impact factor: 3.889

3.  Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis.

Authors:  Yanyun Shu; Yuhu Song; Tao Bai; Xiaoli Pan; Haitao Shang; Ling Yang; Jin Ye; Fan Du
Journal:  J Clin Transl Hepatol       Date:  2021-03-04

4.  Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.

Authors:  Yu-Qing Fang; Dong-Xia Lv; Wei Jia; Jun Li; Yong-Qiong Deng; Yan Wang; Min Yu; Gui-Qiang Wang
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

5.  A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Authors:  Lu Wang; Guan-ya Guo; Jing-bo Wang; Xin-min Zhou; Qiong Yang; Zhe-yi Han; Qiang Li; Jing-wen Zhang; Yun Cai; Xiao-li Ren; Xia Zhou; Rui-Rui Chen; Yong-quan Shi; Ying Han; Dai-ming Fan
Journal:  Sci Rep       Date:  2015-04-20       Impact factor: 4.379

Review 6.  Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.

Authors:  Christopher L Bowlus
Journal:  Hepat Med       Date:  2016-09-01

7.  Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis.

Authors:  Satoru Joshita; Takeji Umemura; Yoko Usami; Yuki Yamashita; Gary L Norman; Ayumi Sugiura; Tomoo Yamazaki; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Koji Igarashi; Kaname Yoshizawa; Masao Ota; Eiji Tanaka
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

Review 8.  Natural history and management of primary biliary cirrhosis.

Authors:  Nadya Al-Harthy; Teru Kumagi
Journal:  Hepat Med       Date:  2012-12-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.